Tharimmune

Tharimmune, Inc. (formerly Hillstream BioPharma, Inc.) is a clinical-stage biotechnology company developing a pipeline of therapeutic candidates in inflammation and immunology. The company’s lead clinical-stage asset, TH104, has been observed to suppress chronic, debilitating pruritus, or “uncontrollable itching,” in PBC, a rare, untreatable orphan liver disease. The company’s early-stage immunology pipeline includes novel multispecific antibodies targeting unique epitopes with new mechanisms of action against known, validated targets in multiple solid tumors, including PD-1, HER2, and HER3.On September 25, 2023, Hillstream BioPharma, Inc. officially changed its name to Tharimmune, Inc.